The Evidence Gap: Why Strong Clinical Data Still Struggle to Secure Market Access
Why strong clinical evidence doesn't always translate into market access and how pharmaceutical companies can bridge the evidence-to-value gap through HEOR, RWE, and market-specific strategies across the GCC, India, and Japan.
Hema Dubey
Nov 2, 2026 12:15
8
